Prof Kalra’s publications 2021-2022


Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022 Nov 4:S0140-6736(22)02083-9.

Pollock RF, Kalra PA, Kalra PR, Ahmed FZ. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose. Adv Ther. 2022 Oct;39(10):4678-4691.

Pullerits K, Garland S, Rengarajan S, Guiver M, Chinnadurai R, Middleton RJ, Chukwu CA, Kalra PA. Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort. Viruses. 2022 Oct 29;14(11):2406.

Wu HHL, Athwal VS, Kalra PA, Chinnadurai R. COVID-19 and hepatorenal syndrome. World J Gastroenterol. 2022 Oct 21;28(39):5666-5678.

Storrar J, Gill-Taylor T, Chinnadurai R, Chrysochou C, Poulikakos D, Rainone F, Ritchie J, Lamerton E, Kalra PA, Sinha S. A low rate of end-stage kidney disease in membranous nephropathy: A single centre study over 2 decades. PLoS One. 2022 Oct 13;17(10):e0276053.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove CA, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jeanes C, Kalra PA, Kyriakidou C, Bradley JM, Munthali C, Minassian AM, McGill F, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, Francisco Ramos AS, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Fries L, Cho I, McKnight I, Glenn G, Rivers EJ, Robertson A, Alves K, Smith K, Toback S. Safety and Efficacy of the NVX-CoV2373 COVID-19 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin Infect Dis. 2022 Oct 10:ciac803.

Wickens O, Rengarajan S, Chinnadurai R, Ford I, Macdougall IC, Kalra PA, Sinha S. The Role of Iron in Calciphylaxis-A Current Review. J Clin Med. 2022 Sep 29;11(19):5779.

Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review. Children (Basel). 2022 Sep 26;9(10):1467.

Grams ME, Brunskill NJ, Ballew SH, Sang Y, Coresh J, Matsushita K, Surapaneni A, Bell S, Carrero JJ, Chodick G, Evans M, Heerspink HJL, Inker LA, Iseki K, Kalra PA, Kirchner HL, Lee BJ, Levin A, Major RW, Medcalf J, Nadkarni GN, Naimark DMJ, Ricardo AC, Sawhney S, Sood MM, Staplin N, Stempniewicz N, Stengel B, Sumida K, Traynor JP, van den Brand J, Wen CP, Woodward M, Yang JW, Wang AY, Tangri N; CKD Prognosis Consortium, Chalmers J, Woodward M, Hsu CY, Ricardo AC, Anderson A, Rao P, Feldman H, Chang AR, Ho K, Green J, Kirchner HL, Bell S, Siddiqui M, Palmer C, Shalev V, Chodick G, Stengel B, Metzger M, Flamant M, Houillier P, Haymann JP, Stempniewicz N, Cuddeback J, Ciemins E, Kovesdy CP, Sumida K, Carrero JJ, Trevisan M, Elinder CG, Wettermark B, Kalra P, Chinnadurai R, Tollitt J, Green D, Coresh J, Ballew SH, Chang AR, Gansevoort RT, Grams ME, Gutierrez O, Konta T, Köttgen A, Levey AS, Matsushita K, Polkinghorne K, Schäffner E, Woodward M, Zhang L, Ballew SH, Chen J, Coresh J, Grams ME, Matsushita K, Sang Y, Surapaneni A, Woodward M. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes. Diabetes Care. 2022 Sep 1;45(9):2055-2063.

Storrar J, Chinnadurai R, Sinha S, Kalra PA. The epidemiology and evolution of IgA nephropathy over two decades: A single centre experience. PLoS One. 2022 Sep 1;17(9):e0268421.

Ali I, Green D, Kalra P, Kalra PA. Experience of a bespoke hyperkalaemia clinic to facilitate prescribing of renin-angiotensin-aldosterone system inhibitors in patients with heart failure with reduced ejection fraction. Cardiorenal Med. 2022 Aug 31.

Kalra PR, Cleland JG, Petrie MC, Ahmed FZ, Foley PW, Kalra PA, Lang NN, Lane RE, Macdougall IC, Pellicori P, Pope MTB, Robertson M, Squire IB, Thomson EA, Ford I. Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart. 2022 Aug 10:heartjnl-2022-321304.

Greenwood SA, Beckley-Hoelscher N, Asgari E, Ayis S, Baker LA, Banerjee D, Bhandari S, Bramham K, Chilcot J, Burton J, Kalra PA, Lightfoot CJ, McCafferty K, Mercer TH, Okonko DO, Oliveira B, Reid C, Smith AC, Swift PA, Mangelis A, Watson E, Wheeler DC, Wilkinson TJ, Reid F, Macdougall IC. The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial. BMC Nephrol. 2022 Jul 27;23(1):268.

Chukwu CA, Rao A, Kalra PA, Middleton R. Managing recurrent urinary tract infections in kidney transplant recipients using smartphone assisted urinalysis test. J Ren Care. 2022 Jun;48(2):119-127.

de Bhailis Á, Al-Chalabi S, Hagemann R, Ibrahim S, Hudson A, Lake E, Chysochou C, Green D, Kalra PA. Managing acute presentations of atheromatous renal artery stenosis. BMC Nephrol. 2022 Jun 16;23(1):210.

Thomson PC, Mark PB, Robertson M, White C, Anker SD, Bhandari S, Farrington K, Jardine AG, Kalra PA, McMurray J, Reddan D, Wheeler DC, Winearls CG, Ford I, Macdougall IC; PIVOTAL Investigators and Committees. An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial. Kidney Int Rep. 2022 May 18;7(8):1793-1801.

De Bhailis ÁM, Kalra PA. Hypertension and the kidneys. Br J Hosp Med (Lond). 2022 May 2;83(5):1-11.

Chukwu CA, Spiers HVM, Middleton R, Kalra PA, Asderakis A, Rao A, Augustine T. Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom. Transplant Rev (Orlando). 2022 Apr;36(2):100686.

Kassianides X, Allgar V, Macdougall IC, Kalra PA, Bhandari S. Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial. Sci Rep. 2022 Apr 27;12(1):6853.

Harwood R, Bridge J, Ressel L, Scarfe L, Sharkey J, Czanner G, Kalra PA, Odudu A, Kenny S, Wilm B, Murray P. Murine models of renal ischemia reperfusion injury: An opportunity for refinement using noninvasive monitoring methods. Physiol Rep. 2022 Mar;10(5):e15211.

Chukwu CA, Mahmood K, Elmakki S, Gorton J, Kalra PA, Poulikakos D, Middleton R. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre. PLoS One. 2022 Mar 10;17(3):e0265130.

Zacharias HU, Altenbuchinger M, Schultheiss UT, Raffler J, Kotsis F, Ghasemi S, Ali I, Kollerits B, Metzger M, Steinbrenner I, Sekula P, Massy ZA, Combe C, Kalra PA, Kronenberg F, Stengel B, Eckardt KU, Köttgen A, Schmid M, Gronwald W, Oefner PJ; GCKD Investigators. A Predictive Model for Progression of CKD to Kidney Failure Based on Routine Laboratory Tests. Am J Kidney Dis. 2022 Feb;79(2):217-230.e1.

Evans M, Morgan AR, Whyte MB, Hanif W, Bain SC, Kalra PA, Davies S, Dashora U, Yousef Z, Patel DC, Strain WD. New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs. 2022 Feb;82(2):97-108.

Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, Małyszko J, Miglinas M, Textor SC, Herzog CA, Johansen KL, Reinecke H, Kalra PA. Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis. 2022 Feb;79(2):289-301.

Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F, Minassian AM, Cho I, Kumar L, Plested JS, Rivers EJ, Robertson A, Dubovsky F, Glenn G, Heath PT; 2019nCoV-302 Study Group. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Feb;10(2):167-179.

Tollitt J, Allan SM, Chinnadurai R, Odudu A, Hoadley M, Smith C, Kalra PA. Does previous stroke modify the relationship between inflammatory biomarkers and clinical endpoints in CKD patients? BMC Nephrol. 2022 Jan 18;23(1):38.

Middleton RJ, Gorton J, O’Riordan E, Knight S, Kalra PA, Poulikakos D. Impact of Shielding and First Dose of COVID-19 Vaccination in Kidney Transplant Recipients. Nephron. 2022;146(1):64-66.

Poulikakos D, Chinnadurai R, Mcgee Y, Gray S, Clough T, Clarke N, Murphy T, Wickens O, Mitchell C, Darby D, Paul J, Chadwick P, Sethi S, Sinha S, Kalra PA, Donne R. A Quality Improvement Project to Minimize COVID-19 Infections in Patients Receiving Haemodialysis and the Role of Routine Surveillance Using Nose and Throat Swabs for SARS-CoV-2 rRT-PCR and Serum Antibody Testing. Nephron. 2022;146(4):335-342.


Flouri D, Lesnic D, Chrysochou C, Parikh J, Thelwall P, Sheerin N, Kalra PA, Buckley DL, Sourbron SP. Motion correction of free-breathing magnetic resonance renography using model-driven registration. MAGMA. 2021 Dec;34(6):805-822.

Wu HHL, Shenoy M, Kalra PA, Chinnadurai R. Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review. Children (Basel). 2021 Dec 22;9(1):3.

Petrie MC, Jhund PS, Connolly E, Mark PB, MacDonald MR, Robertson M, Anker SD, Bhandari S, Farrington K, Kalra PA, Wheeler DC, Tomson CRV, Ford I, McMurray JJV, Macdougall IC; PIVOTAL Investigators and Committees. High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovasc Res. 2021 Dec 7:cvab317.

Kassianides X, Hazara AM, Macdougall IC, Kalra PA, Bhandari S. The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia. Kidney Int Rep. 2021 Nov 24;7(2):322-326.

Jeyalan V, Storrar J, Wu HHL, Ponnusamy A, Sinha S, Kalra PA, Chinnadurai R. Native and transplant kidney histopathological manifestations in association with COVID-19 infection: A systematic review. World J Transplant. 2021 Nov 18;11(11):480-502.

Chinnadurai R, Huckle A, Hegarty J, Kalra PA, Sinha S. Calciphylaxis in end-stage kidney disease: outcome data from the United Kingdom Calciphylaxis Study. J Nephrol. 2021 Oct;34(5):1537-1545.

Wu HHL, Kalra PA, Chinnadurai R. New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review. Vaccines (Basel). 2021 Oct 29;9(11):1252.

Alderson HV, Chinnadurai R, Ibrahim ST, Asar O, Ritchie JP, Middleton R, Larsson A, Diggle PJ, Larsson TE, Kalra PA. Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease. BMC Nephrol. 2021 Oct 2;22(1):329.

Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jamal A, Jeanes C, Kalra PA, Kyriakidou C, McAuley DF, Meyrick A, Minassian AM, Minton J, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Albert G, Cho I, Dubovsky F, Glenn G, Rivers J, Robertson A, Smith K, Toback S; 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021 Sep 23;385(13):1172-1183.

Mark PB, Jhund PS, Walters MR, Petrie MC, Power A, White C, Robertson M, Connolly E, Anker SD, Bhandari S, Farrington K, Kalra PA, Tomson CRV, Wheeler DC, Winearls CG, McMurray JJV, Macdougall IC, Ford I. Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial. Kidney360. 2021 Sep 16;2(11):1761-1769.

Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Saf. 2021 Jul;20(7):757-769

Jhund PS, Petrie MC, Robertson M, Mark PB, MacDonald MR, Connolly E, Anker SD, Bhandari S, Farrington K, Kalra PA, Wheeler DC, Tomson CRV, Ford I, McMurray JJV, Macdougall IC; PIVOTAL Investigators and Committees. Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. JACC Heart Fail. 2021 Jul;9(7):518-527.

Johansen KL, Garimella PS, Hicks CW, Kalra PA, Kelly DM, Martens S, Matsushita K, Sarafidis P, Sood MM, Herzog CA, Cheung M, Jadoul M, Winkelmayer WC, Reinecke H; Conference Participants. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 Jul;100(1):35-48.

Bell JS, James BD, Al-Chalabi S, Sykes L, Kalra PA, Green D. Community- versus hospital-acquired acute kidney injury in hospitalised COVID-19 patients. BMC Nephrol. 2021 Jul 23;22(1):269.

Greenwood SA, Koufaki P, Macdonald JH, Bulley C, Bhandari S, Burton JO, Dasgupta I, Farrington K, Ford I, Kalra PA, Kumwenda M, Macdougall IC, Messow CM, Mitra S, Reid C, Smith AC, Taal MW, Thomson PC, Wheeler DC, White C, Yaqoob M, Mercer TH. Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. Health Technol Assess. 2021 Jun;25(40):1-52.

Greenwood SA, Koufaki P, Macdonald JH, Bhandari S, Burton JO, Dasgupta I, Farrington K, Ford I, Kalra PA, Kean S, Kumwenda M, Macdougall IC, Messow CM, Mitra S, Reid C, Smith AC, Taal MW, Thomson PC, Wheeler DC, White C, Yaqoob M, Mercer TH. Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney Int Rep. 2021 May 30;6(8):2159-2170.

de Bhailís ÁM, Azmi S, Kalra PA. Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Ther Adv Endocrinol Metab. 2021 May 29;12:20420188211020664.

de Bhailís ÁM, Chrysochou C, Kalra PA. Inflammation and Oxidative Damage in Ischaemic Renal Disease. Antioxidants (Basel). 2021 May 25;10(6):845.

Ali I, Donne RL, Kalra PA. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 2021 May 24;22(1):194.

Wickens O, Chinnadurai R, Mannan F, Svendsen F, Baig MY, Chukwu C, Ali I, Summersgill C, Evans D, Antoine BV, Oxton J, Mairs N, Flanagan E, Oliver R, Kalra PA, Poulikakos D. Investigating the utility of COVID-19 antibody testing in end-stage renal disease patients receiving haemodialysis: a cohort study in the United Kingdom. BMC Nephrol. 2021 Apr 27;22(1):154.

Arioli A, Dagliati A, Geary B, Peek N, Kalra PA, Whetton AD, Geifman N. OptiMissP: A dashboard to assess missingness in proteomic data-independent acquisition mass spectrometry. PLoS One. 2021 Apr 15;16(4):e0249771.

Chinnadurai R, Ibrahim ST, Tay T, Bhutani S, Kalra PA. Body weight-based initial dosing of tacrolimus in renal transplantation: Is this an ideal approach? J Ren Care. 2021 Mar;47(1):51-57.

Eddington H, Chinnadurai R, Alderson H, Ibrahim ST, Chrysochou C, Green D, Erekosima I, Hutchison A, Bubtana A, Hegarty J, Kalra PA. A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol. 2021 Mar 23;22(1):106.

Bhandari S, Allgar V, Lamplugh A, Macdougall I, Kalra PA. A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status. BMC Nephrol. 2021 Mar 30;22(1):115.

Ali I, Chinnadurai R, Ibrahim ST, Kalra PA. Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression. BMC Nephrol. 2021 Mar 6;22(1):82.

Raza S, Jokl E, Pritchett J, Martin K, Su K, Simpson K, Birchall L, Mullan AF, Athwal VS, Doherty DT, Zeef L, Henderson NC, Kalra PA, Hanley NA, Piper Hanley K. SOX9 is required for kidney fibrosis and activates NAV3 to drive renal myofibroblast function. Sci Signal. 2021 Mar 2;14(672):eabb4282.

Adam S, Azmi S, Ho JH, Liu Y, Ferdousi M, Siahmansur T, Kalteniece A, Marshall A, Dhage SS, Iqbal Z, D’Souza Y, Natha S, Kalra PA, Donn R, Ammori BJ, Syed AA, Durrington PN, Malik RA, Soran H. Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study. Obes Surg. 2021 Feb;31(2):554-563.

Ali I, Kalra PA. A validation study of the 4-variable and 8-variable kidney failure risk equation in transplant recipients in the United Kingdom. BMC Nephrol. 2021 Feb 9;22(1):57.

Vervloet MG, Boletis IN, de Francisco ALM, Kalra PA, Ketteler M, Messa P, Stauss-Grabo M, Derlet A, Walpen S, Perrin A, Ficociello LH, Rottembourg J, Wanner C, Cannata-Andía JB, Fouque D. Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study. Clin. Kidney J. 2021 Feb 5;14(7):1770-1779.

Burton JO, Corbett RW, Kalra PA, Vas P, Yiu V, Chrysochou C, Kirmizis D. Recent advances in treatment of haemodialysis. J. R. Soc. Med. 2021 Jan;114(1):30-37.

Wolf M, Auerbach M, Kalra PA, Glaspy J, Thomsen LL, Bhandari S. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. Am J Hematol. 2021 Jan;96(1):E11-E15.

Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol. Dial. Transplant. 2021 Jan 1;36(1):111-120.


Skip to content